Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder

Stock Information for Axsome Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Axsome Therapeutics Inc.

Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019
Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility
Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders' Meeting
Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting
Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.